Tempo Acquires ALM Works to Deliver Integrated Strategic Portfolio Management Offering
22.12.2021 20:17:00 EET | Business Wire | Press release
Tempo Software, the leader in team time management and productivity-enhancing solutions, today announced the acquisition of ALM Works, developer of the Structure for Jira software suite that enables project and program managers to make better decisions, work more efficiently, and deliver predictable results. A top-selling project management solution, ALM Works helps over 5000 organizations worldwide visualize, track and manage progress across large-scale, complex projects. Tempo and ALM Works together will provide the first suite of purpose-built program management apps to meet project, program and portfolio management needs for over 70 million users within the Atlassian Ecosystem.
The combination of Tempo’s team time and capacity management solutions and ALM Works’ project and artifact structuring solutions will enable program managers to easily understand whether key initiatives are on track and meeting strategic objectives. A recent Tempo survey showed that 55% of software development executives reported that they use time tracking insights to inform project and portfolio management. This new combination of Tempo and ALM Works will provide organizations with the visibility required to move between strategy and daily execution, make informed decisions, and share progress with executives and stakeholders.
“For over a decade, ALM Works has set themselves apart within the Atlassian Ecosystem due to their focused efforts on helping bring structure to complex project data,” said Mark Lorion, CEO, Tempo Software. “Through an even tighter integration with ALM Works, we are excited to bring a modern, easy-to-use and scalable program management solution to market and to our many shared customers and partners. Together we will uniquely support the teams who operate within Jira on a daily basis and provide the data that senior leadership teams need to be responsive as they set product strategy for an organization.”
“ALM Works focuses on enabling project and program managers to solve complex problems with our flexible, adaptable Structure solution,” said Igor Sereda, ALM Works CEO. “By bringing ALM Works together with Tempo’s industry-leading time tracking and productivity management suite of products, we’re now well-positioned to deliver the most comprehensive program and portfolio management offering to the market. I am proud of the work our team has accomplished over the past 17 years and look forward to bringing visibility and strategic insights to even more people and teams.”
Combined with the recent acquisition of Roadmunk, the addition of ALM Works strengthens Tempo’s strategic portfolio management offering. As a modern and integrated solution suite, Tempo will meet the growing needs of today’s distributed and complex product organizations who need to project, plan, and adapt based on timely organizational capacity data and insights.
Supporting Resources:
- ALM Works website: https://almworks.com/
- Tempo website: https://www.tempo.io
- ALM Works blog: https://almworks.com/blog.html
- Tempo blog: https://www.tempo.io/blog
About Tempo
Tempo Software offers integrated applications for time management, resource planning, and budget management for software engineering and product management teams. Our customers gain an unrivaled understanding of time and effort, and they improve how their teams plan and manage their work. This provides an aligned understanding of and plan for how time –the most precious, and finite resource–is optimized. Tempo Software is seamlessly integrated across popular DevOps tools and a natural and automated part of users’ workflows.
Headquartered in Boston and with offices in Reykjavik, Iceland and Montreal, Canada, Tempo Software is one of the largest and most successful companies in the Atlassian ecosystem.
Tempo has more than 20,000 customers across a range of industries in more than 100 countries. It works with hundreds of partners around the world, offering resale, training, and consultancy in local languages. Tempo is available in English, French, German, Spanish, Portuguese, and Russian, with Japanese coming soon. To learn more about Tempo, visit www.tempo.io
About ALM Works
ALM Works provides software products to empower project managers around the world with visibility and control. ALM Works’ flagship product, Structure for Jira, is a project and portfolio management tool for Atlassian, used by thousands of customers in over 100 countries. Structure, together with its extensions such as Structure.Gantt, is made for project managers and other people responsible for planning, tracking, and getting things done at an organization. It allows them to work efficiently, deliver predictable results, see problems earlier, make better decisions and communicate with clarity and confidence to their teams, managers and clients.
ALM Works is headquartered in Boston with offices in Saint-Petersburg, Russia. To learn more about ALM Works, visit almworks.com.
About Diversis Capital, L.P.
Founded in 2013, Diversis is a software and technology focused private equity fund with $1bn+ in AUM that invests in lower middle-market companies, targeting situations where it can add unique value in helping a company reach the next level. With a collaborative approach to investing, its Operating Partners and Strategic Advisors work alongside management teams to help build successful organizations positioned for long-term growth. To learn more, visit www.diversis.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211222005442/en/
Contact information
Escalate PR for Tempo.io
tempo@escalatepr.com
Joel Richman
joel@escalatepr.com
+1 617 312 5942
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 09:00:00 EEST | Press release
Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521069859/en/ Boomi Named One of The Sunday Times Best Places to Work 2026 Boomi's results speak to a workplace culture that goes well beyond industry norms. The company achieved an average employee happiness score of 86%, rated Excellent, with consistent scores across all six dimensions of WorkL's framework. Most strikingly, Boomi's flight risk, the proportion of employees who may be considering leaving, stood at just 3%, against a technology se
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
